Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019046711) COMPOUNDS AND COMPOSITIONS FOR IRE1 INHIBITION
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/046711 International Application No.: PCT/US2018/049081
Publication Date: 07.03.2019 International Filing Date: 31.08.2018
IPC:
A61K 31/4985 (2006.01) ,C07D 487/04 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
4985
Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
487
Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/-C07D477/183
02
in which the condensed system contains two hetero rings
04
Ortho-condensed systems
Applicants:
OPTIKIRA LLC [US/US]; 20600 Chagrin Boulevard, Suite 210 Cleveland, Ohio 44122, US
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 1111 Franklin Street, 12 Floor Oakland, California 94607, US
Inventors:
KEENAN, Richard M.; US
BACKES, Bradley J.; US
MALY, Dustin J.; US
REYNOLDS, Charles; US
WHITTAKER, Ben; US
KNIGHT, Jamie; US
SUTTON, Jon; US
HYND, George; US
PAPA, Feroz, R.; US
OAKES, Scott, A.; US
Agent:
DOYLE, Kathryn; US
EDDE, Chantal; US
LANDRY, Brian; US
SILVA, Domingos J.; US
SIMPSON, Mark D.; US
MANAS, Michael; US
PLEHN-DUJOWICH, Debora; US
CROTTY, Justin; US
YOUNG, Jacque; US
Priority Data:
62/553,32001.09.2017US
Title (EN) COMPOUNDS AND COMPOSITIONS FOR IRE1 INHIBITION
(FR) COMPOSÉS ET COMPOSITIONS POUR L'INHIBITION DE IRE1
Abstract:
(EN) The present invention provides novel compounds, compositions and methods for treating or preventing an IRE1α-related disease or disorder. In certain embodiments, the disease or disorder is selected from the group consisting of a neurodegenerative disease, a demyelinating disease, cancer, an eye disease, a fibrotic disease, and diabetes.
(FR) La présente invention concerne des nouveaux composés, compositions et méthodes pour traiter ou prévenir une maladie ou un trouble lié à IRE1α. Dans certains modes de réalisation, la maladie ou le trouble est sélectionné dans le groupe constitué par une maladie neurodégénérative, une maladie démyélinisante, un cancer, une maladie oculaire, une maladie fibrotique et un diabète.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)